Alexa R Roberts, Nikhil Vallabhaneni, Brett W Russi, Kayla M Delaney, Jennifer W Leiding, Anthony A Sochet
{"title":"阿奇霉素治疗毛细支气管炎危重症儿童:美国儿科健康信息系统注册研究,2013-2022。","authors":"Alexa R Roberts, Nikhil Vallabhaneni, Brett W Russi, Kayla M Delaney, Jennifer W Leiding, Anthony A Sochet","doi":"10.1097/PCC.0000000000003724","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To estimate prescribing rates for azithromycin as immunomodulation among critically ill children hospitalized for acute bronchiolitis and identify institutional and chronological prescribing variation.</p><p><strong>Design: </strong>Multicenter, observational, retrospective cohort study using the Pediatric Health Information Systems registry from 2013 to 2022.</p><p><strong>Setting: </strong>Forty-seven PICUs in the United States.</p><p><strong>Patients: </strong>Critically ill children 0-3 years old hospitalized for acute viral bronchiolitis excluding those prescribed azithromycin with alternative indication (i.e., concurrent Bordetella pertussis infection, urethritis, atypical pneumonia, acute upper respiratory infections, and asthma-related diagnoses).</p><p><strong>Interventions: </strong>Azithromycin prescription during hospitalization.</p><p><strong>Measurements and main results: </strong>A total of 82,677 children met study criteria of which 3,161 (3.8%) were prescribed azithromycin. Mean (± sd ) center-specific azithromycin prescribing rates exhibited a multilinear decreasing trend (joinpoint breakpoint noted in 2017) going from 4.0% ± 4.6% in 2013 to 2.2% ± 0.8% in 2022 (-0.7%/yr). The median institutional azithromycin prescribing rate was 2.8% (interquartile range [IQR], 1.8-3.9%; total range, 1.2-24.3%). Compared with those not prescribed azithromycin, receipt of azithromycin was associated with the following: older age (median, 10 mo [IQR, 3.2-20.3 mo] vs. 7.8 mo [IQR, 2.9-15.2 mo]; p < 0.001); receiving corticosteroids (57.1% vs. 38.1%; p < 0.001) or continuous albuterol (35.9% vs. 22.4%; p < 0.001); use of noninvasive respiratory support (13.4% vs. 9.7%; p < 0.001) or invasive ventilation (35.9% vs. 22.4%; p < 0.001); and extracorporeal life support (0.5% vs. 0.1%; p < 0.001).</p><p><strong>Conclusions: </strong>In this 2013-2022, U.S. multicenter registry-based cohort study, the azithromycin prescribing rate for critically ill children with bronchiolitis was 3.8%. Exposure varied by institution, patient age, and revealed a decreasing trend over the last decade.</p>","PeriodicalId":19760,"journal":{"name":"Pediatric Critical Care Medicine","volume":" ","pages":"e708-e717"},"PeriodicalIF":4.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Azithromycin for Critically Ill Children With Bronchiolitis: A U.S. Pediatric Health Information Systems Registry Study, 2013-2022.\",\"authors\":\"Alexa R Roberts, Nikhil Vallabhaneni, Brett W Russi, Kayla M Delaney, Jennifer W Leiding, Anthony A Sochet\",\"doi\":\"10.1097/PCC.0000000000003724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To estimate prescribing rates for azithromycin as immunomodulation among critically ill children hospitalized for acute bronchiolitis and identify institutional and chronological prescribing variation.</p><p><strong>Design: </strong>Multicenter, observational, retrospective cohort study using the Pediatric Health Information Systems registry from 2013 to 2022.</p><p><strong>Setting: </strong>Forty-seven PICUs in the United States.</p><p><strong>Patients: </strong>Critically ill children 0-3 years old hospitalized for acute viral bronchiolitis excluding those prescribed azithromycin with alternative indication (i.e., concurrent Bordetella pertussis infection, urethritis, atypical pneumonia, acute upper respiratory infections, and asthma-related diagnoses).</p><p><strong>Interventions: </strong>Azithromycin prescription during hospitalization.</p><p><strong>Measurements and main results: </strong>A total of 82,677 children met study criteria of which 3,161 (3.8%) were prescribed azithromycin. Mean (± sd ) center-specific azithromycin prescribing rates exhibited a multilinear decreasing trend (joinpoint breakpoint noted in 2017) going from 4.0% ± 4.6% in 2013 to 2.2% ± 0.8% in 2022 (-0.7%/yr). The median institutional azithromycin prescribing rate was 2.8% (interquartile range [IQR], 1.8-3.9%; total range, 1.2-24.3%). Compared with those not prescribed azithromycin, receipt of azithromycin was associated with the following: older age (median, 10 mo [IQR, 3.2-20.3 mo] vs. 7.8 mo [IQR, 2.9-15.2 mo]; p < 0.001); receiving corticosteroids (57.1% vs. 38.1%; p < 0.001) or continuous albuterol (35.9% vs. 22.4%; p < 0.001); use of noninvasive respiratory support (13.4% vs. 9.7%; p < 0.001) or invasive ventilation (35.9% vs. 22.4%; p < 0.001); and extracorporeal life support (0.5% vs. 0.1%; p < 0.001).</p><p><strong>Conclusions: </strong>In this 2013-2022, U.S. multicenter registry-based cohort study, the azithromycin prescribing rate for critically ill children with bronchiolitis was 3.8%. Exposure varied by institution, patient age, and revealed a decreasing trend over the last decade.</p>\",\"PeriodicalId\":19760,\"journal\":{\"name\":\"Pediatric Critical Care Medicine\",\"volume\":\" \",\"pages\":\"e708-e717\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Critical Care Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PCC.0000000000003724\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Critical Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PCC.0000000000003724","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的:估计阿奇霉素作为免疫调节剂在急性细支气管炎住院的危重儿童中的处方率,并确定机构和时间上的处方差异。设计:多中心、观察性、回顾性队列研究,使用2013 - 2022年儿科健康信息系统登记。环境:美国有47个picu。患者:因急性病毒性细支气管炎住院的0-3岁危重儿童,不包括阿奇霉素处方中有其他适应症的儿童(即并发百日咳博德泰拉感染、尿道炎、非典型肺炎、急性上呼吸道感染和哮喘相关诊断)。干预措施:住院期间开阿奇霉素。测量结果和主要结果:共有82677名儿童符合研究标准,其中3161名(3.8%)儿童使用阿奇霉素。平均(±sd)中心特异性阿奇霉素处方率呈现多线性下降趋势(2017年发现连接点断点),从2013年的4.0%±4.6%降至2022年的2.2%±0.8%(-0.7%/年)。机构阿奇霉素处方率中位数为2.8%(四分位数间距[IQR], 1.8-3.9%;总范围:1.2-24.3%)。与未使用阿奇霉素的患者相比,阿奇霉素的使用与以下因素相关:年龄较大(中位数,10个月[IQR, 3.2-20.3个月]vs. 7.8个月[IQR, 2.9-15.2个月];P < 0.001);接受皮质类固醇(57.1% vs. 38.1%;P < 0.001)或连续使用沙丁胺醇(35.9% vs. 22.4%;P < 0.001);使用无创呼吸支持(13.4% vs. 9.7%;P < 0.001)或有创通气(35.9% vs. 22.4%;P < 0.001);体外生命支持(0.5% vs. 0.1%;P < 0.001)。结论:在2013-2022年美国多中心注册队列研究中,重症毛细支气管炎患儿阿奇霉素处方率为3.8%。暴露因机构、患者年龄而异,并在过去十年中呈现下降趋势。
Azithromycin for Critically Ill Children With Bronchiolitis: A U.S. Pediatric Health Information Systems Registry Study, 2013-2022.
Objectives: To estimate prescribing rates for azithromycin as immunomodulation among critically ill children hospitalized for acute bronchiolitis and identify institutional and chronological prescribing variation.
Design: Multicenter, observational, retrospective cohort study using the Pediatric Health Information Systems registry from 2013 to 2022.
Setting: Forty-seven PICUs in the United States.
Patients: Critically ill children 0-3 years old hospitalized for acute viral bronchiolitis excluding those prescribed azithromycin with alternative indication (i.e., concurrent Bordetella pertussis infection, urethritis, atypical pneumonia, acute upper respiratory infections, and asthma-related diagnoses).
Interventions: Azithromycin prescription during hospitalization.
Measurements and main results: A total of 82,677 children met study criteria of which 3,161 (3.8%) were prescribed azithromycin. Mean (± sd ) center-specific azithromycin prescribing rates exhibited a multilinear decreasing trend (joinpoint breakpoint noted in 2017) going from 4.0% ± 4.6% in 2013 to 2.2% ± 0.8% in 2022 (-0.7%/yr). The median institutional azithromycin prescribing rate was 2.8% (interquartile range [IQR], 1.8-3.9%; total range, 1.2-24.3%). Compared with those not prescribed azithromycin, receipt of azithromycin was associated with the following: older age (median, 10 mo [IQR, 3.2-20.3 mo] vs. 7.8 mo [IQR, 2.9-15.2 mo]; p < 0.001); receiving corticosteroids (57.1% vs. 38.1%; p < 0.001) or continuous albuterol (35.9% vs. 22.4%; p < 0.001); use of noninvasive respiratory support (13.4% vs. 9.7%; p < 0.001) or invasive ventilation (35.9% vs. 22.4%; p < 0.001); and extracorporeal life support (0.5% vs. 0.1%; p < 0.001).
Conclusions: In this 2013-2022, U.S. multicenter registry-based cohort study, the azithromycin prescribing rate for critically ill children with bronchiolitis was 3.8%. Exposure varied by institution, patient age, and revealed a decreasing trend over the last decade.
期刊介绍:
Pediatric Critical Care Medicine is written for the entire critical care team: pediatricians, neonatologists, respiratory therapists, nurses, and others who deal with pediatric patients who are critically ill or injured. International in scope, with editorial board members and contributors from around the world, the Journal includes a full range of scientific content, including clinical articles, scientific investigations, solicited reviews, and abstracts from pediatric critical care meetings. Additionally, the Journal includes abstracts of selected articles published in Chinese, French, Italian, Japanese, Portuguese, and Spanish translations - making news of advances in the field available to pediatric and neonatal intensive care practitioners worldwide.